Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial.

@article{Dimitroulopoulos2007LongAO,
  title={Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial.},
  author={Dimitrios A Dimitroulopoulos and Dimitrios N Xinopoulos and Klisthenis Tsamakidis and Athanassios Zisimopoulos and Efthymios Andriotis and Demosthenes P Panagiotakos and Aikaterini Fotopoulou and Christina A Chrysohoou and Athanassios Bazinis and Dimitra Daskalopoulou and Emmanuel Paraskevas},
  journal={World journal of gastroenterology},
  year={2007},
  volume={13 23},
  pages={3164-70}
}
AIM To estimate if and to what extent long acting octreotide (LAR) improves survival and quality of life in patients with advanced hepatocellular carcinoma (HCC). METHODS A total of 127 cirrhotics, stages A-B, due to chronic viral infections and with advanced HCC, were enrolled in the study. Scintigraphy with 111Indium labeled octreotide was performed in all cases. The patients with increased accumulation of radionuclear compound were randomized to receive either oral placebo only or… CONTINUE READING